Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2016-11-11 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
关于公司控股股东部分股份质押及解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement from a company regarding the pledge and release of shares held by a major shareholder. It details the number of shares pledged, dates, pledgees, and the proportion of shares involved. There is no financial performance data, no mention of financial results, no management discussion, no legal proceedings, no merger or acquisition activity, and no meeting or voting information. The document is a regulatory announcement about share pledging activities by a controlling shareholder. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels or related shareholding activities such as pledges.
2016-11-11 Chinese
关于子公司收到药品GMP证书及药品补充申请批件的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about its subsidiary receiving a GMP certificate and drug supplementary application approvals from regulatory authorities. It contains no financial data, no discussion of financial results, no management commentary on financial performance, and no mention of shareholder meetings or voting results. The document is a regulatory announcement about operational and compliance matters related to pharmaceutical production certifications and approvals. It is relatively short (2333 characters) and serves to inform investors and the public about regulatory approvals and changes in certification status. This fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2016-11-08 Chinese
国都证券股份有限公司关于公司终止部分募集资金投资项目并将剩余募集资金永久补充流动资金的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from the sponsor (Guodu Securities) regarding the termination of part of a fundraising investment project by Fuan Pharmaceutical (Group) Co., Ltd. and the permanent allocation of remaining raised funds to working capital. It references regulatory rules from the Shenzhen Stock Exchange and the China Securities Regulatory Commission, discusses fundraising amounts, project progress, reasons for termination, and approvals by the board and supervisory committee. The document is a formal verification and opinion letter from the sponsor, not a full financial report or earnings release. It is not an announcement of voting results or a proxy solicitation. It is a regulatory compliance-related verification document concerning fundraising use and project changes. The document length is about 4,000 characters, which is relatively short and focused on verification rather than full financial data. Therefore, it fits best under Regulatory Filings (RNS) as a compliance and verification filing rather than a full Annual Report, Interim Report, or Capital/Financing Update.
2016-10-28 Chinese
关于向全资子公司增加注册资本的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the increase of registered capital in two wholly-owned subsidiaries by the parent company. It details the investment amount, purpose, and financial status of the subsidiaries. The document is a formal announcement of a capital increase, not a full financial report or audit. It does not contain comprehensive financial statements or detailed financial analysis typical of Annual Reports (10-K) or Interim Reports (IR). It also does not fit into categories like Earnings Release or Management Reports. The content clearly relates to capital structure changes through additional investment in subsidiaries, which aligns with the Capital/Financing Update category (CAP). The document length is short (2265 characters), and it is not merely announcing the publication of a report but is itself the announcement of a capital increase.
2016-10-28 Chinese
第三届监事会第十一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the 11th meeting of the 3rd Supervisory Board of the company 福安药业 (Fuan Pharmaceutical). It includes approval of the 2016 third quarter report, decisions on the use of idle raised funds for cash management, and termination of some fundraising investment projects. The document is short (1129 characters) and primarily reports on meeting decisions and approvals rather than containing the full quarterly report or detailed financial data. It is an announcement of meeting resolutions and approvals, not the report itself. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2016-10-28 Chinese
第三届董事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 12th meeting of the 3rd Board of Directors of the company 福安药业 (Fuan Pharmaceutical). It includes voting results on various proposals such as approval of the 2016 third quarter report, changes in registered capital, amendments to the company charter, and plans for a shareholders meeting. The document is an official announcement of board decisions and voting outcomes rather than the full financial report or detailed management discussion. It also references that the actual reports and detailed announcements are published separately on the regulatory website. The document length is short (1580 characters) and primarily serves to disclose board meeting resolutions and voting results. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2016-10-28 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.